Screening LDCT Catches a 1.6 cm Peripheral SCLC — Before Symptoms

A 63-year-old African American woman with asthma, obstructive sleep apnea, hypertension, diabetes mellitus, and heart failure with reduced ejection fraction presented to the pulmonary clinic for lung cancer screening. She was an active smoker with an extensive smoking history — approximately one to two cigarettes daily — but had no hemoptysis, weight loss, or other constitutional symptoms. Physical examination was unremarkable.

Figure 1

LDCT chest: 1.6 cm solitary nodule, right lower lobe — screening detection

Low-dose CT demonstrating a 1.6 cm solid nodule in the superior segment of the right lower lobe without hilar or mediastinal lymphadenopathy. This is the screening success scenario: SCLC detected at a peripheral, node-negative stage before it produced any symptoms. Peripheral SCLC without nodal involvement comprises fewer than 5% of SCLC cases — the overwhelming majority present with central masses and bulky mediastinal disease. This nodule was caught precisely because the patient was enrolled in a screening program.

In May, routine LDCT screening revealed the 1.6 cm solid right lower lobe nodule with no significant hilar or mediastinal lymphadenopathy. Further evaluation was delayed four months due to the patient's travel. A subsequent PET scan in late September demonstrated intense FDG uptake confined entirely to the right lower lobe nodule — no distant metastasis or locoregional nodal involvement. The PET showed a single metabolically active lesion: the ideal presentation for potentially curative resection.

Figure 2

PET-CT: intense FDG uptake localized to the RLL nodule — no nodal spread

Intense FDG uptake tightly localized to the right lower lobe nodule (yellow arrows) with no regional nodal or distant metastasis — confirming very-limited-stage disease. In the four-month interval between LDCT detection and PET, the cancer had not spread. But it was growing: the six-month interval from LDCT to bronchoscopy would reveal 40% size increase, consistent with SCLC's 30–80 day volume doubling time.

In early November, following optimization of her heart failure, the patient underwent robotic-navigational bronchoscopy with endobronchial ultrasound. Interval CT imaging at the time of the procedure demonstrated growth of the lesion from 1.6 cm to 2.2 × 1.4 cm over approximately six months — a volumetrically substantial expansion that strongly predicted high-grade neuroendocrine histology. Transbronchial biopsies, needle aspiration, and bronchoalveolar lavage of the right lower lobe lesion were performed, alongside biopsies of lymph node stations 11R, 7, and 11L.

Figure 3

Interval CT: 1.6 cm → 2.2 × 1.4 cm in six months — SCLC kinetics

CT obtained prior to robotic bronchoscopy demonstrates marked interval growth (red arrows). This rate of expansion — approximately doubling in volume over six months — corresponds to a volume doubling time of roughly 60–80 days, directly within the SCLC range (30–80 days) and far faster than typical adenocarcinoma (150–400 days). This kinetics data should have accelerated biopsy: a nodule growing at SCLC rates demands expedited tissue diagnosis, not continued surveillance.

Cytopathology revealed nests of small round blue cells with hyperchromatic nuclei, scant cytoplasm, and prominent crush artifact — a cytopathologic signature of SCLC's fragile nuclear architecture. Immunohistochemistry demonstrated strong positivity for TTF-1 and synaptophysin, focal weak positivity for chromogranin, and negativity for p40 and Napsin A — confirming SCLC and ruling out squamous cell carcinoma and adenocarcinoma. Ki-67 proliferative index was markedly elevated at greater than 80–90%. All sampled lymph nodes were negative for malignancy, maintaining the T1c N0 M0 staging.

Figure 4

Histopathology and IHC: SCLC confirmed with Ki-67 >80%

(A) H&E: small round blue cells with hyperchromatic nuclei, scant cytoplasm, and crush artifact. (B) TTF-1: diffuse nuclear positivity confirming primary lung origin. (C) Synaptophysin: strong cytoplasmic positivity confirming neuroendocrine differentiation. (D) Ki-67: proliferative index >80%, distinguishing SCLC from carcinoid (typically <30%). Negative p40 and Napsin A exclude squamous cell carcinoma and adenocarcinoma respectively.

Given tumor size less than 3 cm and the absence of nodal metastasis, she was staged as limited-stage SCLC, clinically IA (T1c N0 M0). Per NCCN guidelines for very-limited-stage SCLC, she was a candidate for curative surgical resection. Tragically, before surgical intervention could occur, she succumbed to complications from her severe cardiovascular and respiratory comorbidities — a sobering reminder that even early-stage cancer cannot be treated in isolation from a patient's overall physiological reserve.

Discussion

This case is simultaneously a screening success and a system failure. It is a screening success because LDCT detected SCLC at its only potentially curable stage — peripheral T1c N0 M0, amenable to surgical resection under NCCN guidelines. Fewer than 5% of SCLC patients ever present at this stage. Without screening, this tumor would have declared itself as central bulky disease with mediastinal lymphadenopathy, at which point survival is measured in months rather than years. The system failed the patient not through detection but through tempo: a four-month delay to PET (travel) followed by another two-month delay to bronchoscopy (cardiac optimization) allowed a 30–80 day doubling-time tumor six months to grow 40% before tissue was obtained — and then the window for surgery closed due to her comorbidities before the procedure could be scheduled.

The structural lesson is tumor kinetics. A nodule with suspected SCLC growth kinetics — a doubling time of less than 90 days — should not be managed on the same timeline as suspected adenocarcinoma. The NLST and NELSON trial protocols were designed around adenocarcinoma kinetics; applying them to a high-grade neuroendocrine tumor creates a dangerous mismatch. When a nodule grows rapidly in a screening patient, expedited biopsy — not the next surveillance interval — is the appropriate response. For physiologically frail patients like this one who are deemed too high-risk for surgery, SBRT has emerged as an effective alternative with local control rates of 80–95% at two years for limited-stage peripheral SCLC.